Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
|Videos|March 8, 2017
Women Facing Stigma: The Parallel Between Zika and HIV
Author(s)Contagion Editorial Staff
Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, discusses the social stigma surrounding Zika- and HIV-positive women.
Advertisement
Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, discusses the social stigma surrounding Zika- and HIV- positive women.
Interview Transcript (slightly modified for readability)
“I think there’s a parallel between Zika and HIV not because they are similar viruses or any of that, but the social impact and our response. There’s stigma; the pregnant women with Zika infection do not disclose. They’re afraid. They’re afraid of you to judge them [and say], ‘why did you get Zika? Weren’t you using condoms? Weren’t you using mosquito repellent? You did not take care of yourself.’
[These women] are afraid of being blamed [for] getting Zika. They are afraid, of course, of having a baby with a disability. That’s also part of the concern of any pregnant woman as well, the health of the baby. I’ve had [female patients] whose partners abandoned them because they found out that they had Zika, and so, there’s stigma. There’s a lot of concern, communication is not clear. People have a lot of misperceptions about Zika.
It is not the same, absolutely. HIV and Zika [are] not the same. But, I think Zika concerns me because it causes birth defects. That’s the main issue with Zika, it causes birth defects, and this is why it is something that we need to make sure that we can control. We need treatments, we need vaccines, we need vector control, we need to make sure that women get access to contraception, access to healthcare, access to prenatal care, and access to quality healthcare.”
Advertisement
Related to this article
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.
Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
4
Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point
5